A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Clinical trial NCT05023980 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05023980
- Sponsor
- Loxo Oncology, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-23
- Primary completion
- 2025-07-11
- Enrollment
- 309
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.